Vivosim Labs, Inc. (VIVS) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vivosim Labs, Inc. on July 16, 2026. The filing discloses the entry into material definitive agreements regarding a private placement of equity securities and related warrant amendments.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.0 million from the sale of pre-funded warrants and accompanying common warrants.
- Securities Issued: 4,705,883 pre-funded warrants and 4,705,883 common warrants.
- Purchase Price: $0.85 per share of Common Stock subject to the Pre-Funded Warrants and accompanying Common Warrant.
- Placement Agent Fee: 6.50% of gross proceeds payable to A.G.P./Alliance Global Partners.
- Use of Proceeds: Working capital and general corporate purposes.
- Closing Date: Expected on or about July 17, 2026.
Note: This filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the company's operations.
Material Changes and Agreements
- Securities Purchase Agreement: Entered into with an accredited institutional investor. Includes a 60-day lock-up period on issuing additional common stock or equivalents after the registration statement for resale is declared effective.
- Warrant Terms:
- Pre-Funded Warrants: Exercise price of $0.001; exercisable immediately; cash or cashless basis.
- Common Warrants: Exercise price of $0.85; exercisable after stockholder approval for a five-year period; generally cash basis, with cashless option if resale registration is not effective.
- Beneficial Ownership Limitations: Exercise is restricted if it causes the holder to exceed 9.99% ownership for Pre-Funded Warrants or 4.99% for Common Warrants (adjustable with notice, capped at 9.99%).
- Armistice Warrant Amendment: Amended existing warrants issued to Armistice Capital Master Fund Ltd. to align the exercise price to $0.85 and extend the termination date to five years after stockholder approval.
Guidance, Outlook, and Risks
The Company intends to utilize the proceeds for working capital and general corporate purposes. The filing includes standard forward-looking statements cautioning that actual results may differ due to financial position, market conditions, and other risks detailed in periodic reports. The Company does not intend to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent fees and offering expenses.
- Confirm the status of the registration statement for the resale of Warrant Shares to determine when the 60-day lock-up period expires.
- Review the Company's most recent periodic reports (10-K/10-Q) for current liquidity, cash position, and debt levels, as this 8-K does not contain operational financial data.
- Monitor the timeline for obtaining stockholder approval required for the exercise of Common Warrants and the amended Armistice Warrants.
- Check for any subsequent filings regarding the beneficial ownership of the Purchaser to ensure compliance with the 9.99% and 4.99% exercise limitations.